스프라이셀(Sprycel) 시장 보고서(2025년)

Sprycel is a prescription drug mainly prescribed for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It works by targeting specific proteins that drive the growth of cancer cells, helping to stop the unchecked multiplication of leukemia cells. This targeted therapy is especially beneficial for patients who do not respond to or cannot tolerate other treatment options.

The primary indications for Sprycel include chronic myeloid leukemia and acute lymphoblastic leukemia. CML is a slowly developing cancer of the blood and bone marrow, caused by a genetic alteration known as the Philadelphia chromosome. Sprycel is available in various dosage forms, including tablets and oral suspension, and is distributed through hospitals, clinics, retail and online pharmacies, as well as specialty pharmacies.

The sprycel market research report is one of a series of new reports from The Business Research Company that provides sprycel market statistics, including sprycel industry global market size, regional shares, competitors with a sprycel market share, detailed sprycel market segments, market trends and opportunities, and any further data you may need to thrive in the sprycel industry. This sprycel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sprycel market size has grown steadily in recent years. It will grow from $2.07 billion in 2024 to $2.17 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth observed during the historic period can be attributed to several factors, including a rise in the incidence of chronic myeloid leukemia, widespread use as a frontline treatment, advancements in diagnostic methods, expansion of the oncology drug pipeline, and the implementation of government reimbursement initiatives.

The sprycel market size is expected to see steady growth in the next few years. It will grow to $2.60 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. The projected growth in the forecast period can be linked to the rising global cancer burden, approvals for pediatric indications, expansion of oncology therapeutics, ongoing trials involving combination therapies, and a focus on sustainable pharmaceutical manufacturing. Key trends expected during this period include progress in combination treatment approaches, increased adoption of personalized medicine, innovation in patient-friendly drug formulations, updates in treatment guidelines, and a continued shift toward targeted cancer therapies.

The growing prevalence of leukemia is expected to drive the expansion of the Sprycel market in the coming years. Leukemia, a cancer affecting the blood and bone marrow, is marked by the excessive production of abnormal white blood cells. This increase in leukemia cases is largely linked to the aging population, as older individuals are more susceptible to the disease, leading to a rise in diagnoses. Sprycel (dasatinib) is an effective treatment for specific types of leukemia, including Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), as it inhibits the BCR-ABL protein responsible for cancer cell growth. For example, the American Cancer Society (ACS), a U.S.-based nonprofit organization focused on eliminating cancer, reported that approximately 59,610 individuals were diagnosed with leukemia in 2023, resulting in around 23,940 deaths. Consequently, the rising incidence of leukemia is contributing to the growth of the Sprycel market.

The increase in healthcare expenditure is also expected to support the growth of the Sprycel market. Healthcare expenditure refers to the total financial resources allocated to healthcare services and products within a specific region or over a certain period. This expenditure is rising due to technological advancements in medicine, which lead to the adoption of high-cost diagnostic tools and treatments that improve health outcomes. Increased spending on healthcare facilitates broader access to innovative cancer therapies such as Sprycel by enabling medical institutions to invest in advanced oncology treatments. For instance, in April 2025, the Office for National Statistics in the UK reported that total healthcare spending rose by 6.5% in nominal terms from 2023 to 2024, slightly exceeding the 6.3% growth recorded the previous year. As a result, higher healthcare expenditure is bolstering the Sprycel market's growth.

Key players in the Sprycel market are increasingly focusing on the development of generic versions of the drug to take advantage of the approaching expiration of exclusivity rights and meet the demand for more affordable cancer treatments. A generic version of Sprycel refers to dasatinib-based medications manufactured by other pharmaceutical companies after the original patent expires, offering equivalent therapeutic benefits at reduced costs. For instance, in September 2024, Apotex Corp., a Canadian pharmaceutical company, launched dasatinib tablets, a generic form of Sprycel used to treat certain types of leukemia. Dasatinib is a kinase inhibitor prescribed for adults and children aged one year and older with Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), particularly in patients who do not respond to or cannot tolerate previous treatments. The generic product adheres to stringent quality standards it is latex-free, sugar-free, dye-free, alcohol-free, and preservative-free and is available in bottles containing 30 or 60 tablets, depending on the dosage strength.

Major players in the sprycel market are Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co. Ltd., Beacon Pharmaceuticals Limited, Panacea Biotec Limited, Apotex Corp., Hubei Haosun Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited, Zydus Lifesciences Limited, Biocon Limited, Zentiva k.s., Alembic Pharmaceuticals Limited, Granules India Limited, Natco Pharma Limited, Shilpa Medicare Limited, Prasco Laboratories, Stason Pharmaceuticals Inc., HRV Global Life Sciences Pvt. Ltd., Sichuan Elixir Pharmaceutical Co. Ltd., Gonane Pharma Limited.

Asia-Pacific was the largest region in the sprycel market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in sprycel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sprycel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sprycel market consists of sales of products including film-coated tablets, powder for oral suspension, blister packaging, pediatric dosing packs, and flavoring agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sprycel Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sprycel market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sprycel ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sprycel market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia
• 2) By Dosage Forms: Tablets; Oral Suspension
• 3) By Distribution Channel: Hospitals and Clinics; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies
• Subsegments:
• 1) By Chronic Myeloid Leukemia: Newly Diagnosed Chronic Phase CML; Imatinib-Resistant Or Intolerant CML; Accelerated Phase CML; Blast Phase CML
• 2) By Acute Lymphoblastic Leukemia: Philadelphia Chromosome-Positive (Ph+) ALL In Adults; Philadelphia Chromosome-Positive (Ph+) ALL In Pediatric Patients; Relapsed Or Refractory Ph+ ALL
• Companies Mentioned: Bristol-Myers Squibb Company; Otsuka Pharmaceutical Co. Ltd.; Beacon Pharmaceuticals Limited; Panacea Biotec Limited; Apotex Corp.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Sprycel Market Characteristics

3. Sprycel Market Trends And Strategies

4. Sprycel Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Sprycel Growth Analysis And Strategic Analysis Framework

• 5.1. Global Sprycel PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Sprycel Market Growth Rate Analysis
• 5.4. Global Sprycel Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Sprycel Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Sprycel Total Addressable Market (TAM)

6. Sprycel Market Segmentation

• 6.1. Global Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Myeloid Leukemia
• Acute Lymphoblastic Leukemia
• 6.2. Global Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Oral Suspension
• 6.3. Global Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals and Clinics
• Retail Pharmacies
• Online Parmacies
• Speciality Pharmacies
• 6.4. Global Sprycel Market, Sub-Segmentation Of Chronic Myeloid Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Newly Diagnosed Chronic Phase CML
• Imatinib-Resistant or Intolerant CML
• Accelerated Phase CML
• Blast Phase CML
• 6.5. Global Sprycel Market, Sub-Segmentation Of Acute Lymphoblastic Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Philadelphia Chromosome-Positive (Ph+) ALL in Adults
• Philadelphia Chromosome-Positive (Ph+) ALL in Pediatric Patients
• Relapsed or Refractory Ph+ ALL

7. Sprycel Market Regional And Country Analysis

• 7.1. Global Sprycel Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Sprycel Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Sprycel Market

• 8.1. Asia-Pacific Sprycel Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Sprycel Market

• 9.1. China Sprycel Market Overview
• 9.2. China Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Sprycel Market

• 10.1. India Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Sprycel Market

• 11.1. Japan Sprycel Market Overview
• 11.2. Japan Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Sprycel Market

• 12.1. Australia Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Sprycel Market

• 13.1. Indonesia Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Sprycel Market

• 14.1. South Korea Sprycel Market Overview
• 14.2. South Korea Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Sprycel Market

• 15.1. Western Europe Sprycel Market Overview
• 15.2. Western Europe Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Sprycel Market

• 16.1. UK Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Sprycel Market

• 17.1. Germany Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Sprycel Market

• 18.1. France Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Sprycel Market

• 19.1. Italy Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Sprycel Market

• 20.1. Spain Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Sprycel Market

• 21.1. Eastern Europe Sprycel Market Overview
• 21.2. Eastern Europe Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Sprycel Market

• 22.1. Russia Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Sprycel Market

• 23.1. North America Sprycel Market Overview
• 23.2. North America Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Sprycel Market

• 24.1. USA Sprycel Market Overview
• 24.2. USA Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Sprycel Market

• 25.1. Canada Sprycel Market Overview
• 25.2. Canada Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Sprycel Market

• 26.1. South America Sprycel Market Overview
• 26.2. South America Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Sprycel Market

• 27.1. Brazil Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Sprycel Market

• 28.1. Middle East Sprycel Market Overview
• 28.2. Middle East Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Sprycel Market

• 29.1. Africa Sprycel Market Overview
• 29.2. Africa Sprycel Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Sprycel Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Sprycel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Sprycel Market Competitive Landscape And Company Profiles

• 30.1. Sprycel Market Competitive Landscape
• 30.2. Sprycel Market Company Profiles
  • 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Otsuka Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Beacon Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Panacea Biotec Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Apotex Corp. Overview, Products and Services, Strategy and Financial Analysis

31. Sprycel Market Other Major And Innovative Companies

• 31.1. Hubei Haosun Pharmaceutical Co. Ltd.
• 31.2. Dr. Reddy's Laboratories Ltd.
• 31.3. Lupin Limited
• 31.4. Zydus Lifesciences Limited
• 31.5. Biocon Limited
• 31.6. Zentiva k.s.
• 31.7. Alembic Pharmaceuticals Limited
• 31.8. Granules India Limited
• 31.9. Natco Pharma Limited
• 31.10. Shilpa Medicare Limited
• 31.11. Prasco Laboratories
• 31.12. Stason Pharmaceuticals Inc.
• 31.13. HRV Global Life Sciences Pvt. Ltd.
• 31.14. Sichuan Elixir Pharmaceutical Co. Ltd.
• 31.15. Gonane Pharma Limited

32. Global Sprycel Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sprycel Market

34. Recent Developments In The Sprycel Market

35. Sprycel Market High Potential Countries, Segments and Strategies

• 35.1 Sprycel Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Sprycel Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Sprycel Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer